Cytek Biosciences, Inc.

Historical 13F Holders

Symbol
CTKB
CUSIP
23285D109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 23285D109 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 7.2% 7/8/2026
Event 6/30/2026
Millennium Management LLC 13G/A
7.2% 8/6/2026
Event 6/30/2026
Boston Partners 13G 5.9% 8/4/2026
Event 6/30/2026
Topline Capital Management, LLC 13G
5.3% 11/17/2025
Event 9/25/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Brown Capital Management, LLC 13G/A 3.9% 11/12/2025
Event 9/30/2025
RA Capital Management, L.P. 13G/A
0% 2/14/2025
Event 12/31/2024
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 6 15.1 k $90.2 k
2026 Q2 157 81.5 M $363 M
2026 Q1 167 85.1 M $372 M
2025 Q4 157 82.0 M $414 M
2025 Q3 155 80.4 M $310 M
2025 Q2 161 79.4 M $270 M
2025 Q1 166 77.6 M $311 M
2024 Q4 157 77.3 M $501 M
2024 Q3 141 75.6 M $419 M
2024 Q2 136 77.7 M $433 M
2024 Q1 132 82.4 M $553 M
2023 Q4 111 80.5 M $734 M
2023 Q3 112 77.5 M $428 M
2023 Q2 106 77.0 M $658 M
2023 Q1 108 69.1 M $635 M
2022 Q4 112 66.7 M $681 M
2022 Q3 92 61.2 M $901 M
2022 Q2 86 52.9 M $568 M
2022 Q1 76 47.8 M $515 M
2021 Q4 53 35.0 M $572 M
2021 Q3 55 34.4 M $744 M